CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Three years, countless stories
May 15, 2026
UC's Klekamp Law celebrates its 193rd Hooding with stories from graduates reflecting on their paths through the college.
Driven by curiosity, guided by care
May 14, 2026
Max Wilson, a University of Cincinnati College of Allied Health Sciences health sciences major on the pre-physician assistant track, found his path expanding beyond the classroom and into hands-on research focused on human performance and patient care.
UC Blue Ash celebrates top students and recognizes Honor Student of the Year
May 14, 2026
The University of Cincinnati Blue Ash College recently hosted a special event that celebrated students for exceptional achievements during the 2025-26 academic year. The honorees included academic award winners, student engagement award winners, Latin Honors graduates, and the 2026 UC Blue Ash College Honor Student of the Year.